With little proof, Trump links Tylenol to autism and touts a treatment

Just six months back, the Trump administration made a commitment to uncover the cause of autism. On September 22, prominent health officials in the U.S. unveiled claims of both a cause and a potential treatment; however, these assertions lack robust scientific support, and no evidence has been provided to substantiate them.

During a lengthy news briefing filled with dubious claims, former President Donald Trump asserted that acetaminophen, known commercially in the U.S. as Tylenol, may be a cause of autism, cautioning expectant mothers against its use. He also mentioned leucovorin, a form of folinic acid typically used for mitigating chemotherapy toxicity, suggesting it could alleviate symptoms of autism.

“We’re on the path to saving many children from a challenging life,” Trump proclaimed during the briefing. “We’re also aiming to ease the burdens faced by countless parents.”

Nonetheless, credible evidence linking acetaminophen with autism is minimal, and many autism experts are skeptical about the supposed benefits of leucovorin. While some studies have hinted at a relationship between maternal use of acetaminophen and autism risk, establishing a causative link remains a significant hurdle. Furthermore, a large-scale study published in JAMA involving nearly 2.5 million children in Sweden found no evidence supporting any association between acetaminophen during pregnancy and autism, attention-deficit/hyperactivity disorder, or intellectual disability, reinforcing the notion that other factors might play a more crucial role.

The Coalition of Autism Scientists, a network of over 250 autism researchers, clearly articulated that “the data cited do not support the assertion that Tylenol causes autism and leucovorin serves as a cure. Such claims only provoke fear and foster false hope in the absence of clear answers.”

As autism rates continue to escalate—affecting 1 in 31 children as of 2022—the Trump administration has suggested that toxins or environmental factors are largely responsible for this increase, ignoring the more plausible explanations of heightened awareness and improved screening techniques.

Despite recent claims, experts like Dennis Kuo, a pediatrician at the University of Rochester Medical Center, have pointed out the glaring lack of evidence linking acetaminophen to autism. “The wealth of scientific literature is inconclusive, and even recent studies confirm that generalizing this relationship is misguided.”

There are additional complexities at play; autism is largely driven by genetics, and patterns show that families with a history of autism are more likely to have children on the spectrum. Noor Pervez, community engagement manager at the Autistic Self Advocacy Network, echoes these sentiments, stating, “It’s crucial to recognize that the actions of parents during pregnancy are not responsible for a child’s autism.”

Peeking into the discourse surrounding autism, it becomes evident that attributing a singular cause to this multifaceted condition is an oversimplification. Kuo emphasizes that the intricate nature of autism demands a broader perspective rather than an unhealthy focus on potential culprits.

In contrast to Trump’s recommendations to avoid acetaminophen completely during pregnancy, experts argue such advice could pose more risks than benefits. Steven J. Fleischman, president of the American College of Obstetricians and Gynecologists noted, “Using acetaminophen to maintain health during pregnancy is generally far less risky than the medical complications associated with pain and fever.”

Additionally, certain medical conditions, like fevers during pregnancy, have been linked to increased risks of autism and other disorders, further complicating the narrative. Pervez argues that discouraging safe pain relief options could lead to unnecessary hardship for pregnant individuals, including those with autism.

Alongside acetaminophen claims, the announcement introduced leucovorin as a potential treatment for autism symptoms, again with inadequate scientific backing. Although the FDA plans to update the drug’s labeling, experts like Kevin Klatt from the University of California, Berkeley, urge caution, describing existing studies as largely limited in scope and advocating for substantial clinical trials before endorsing widespread use.

Framing autism as an “epidemic” in need of urgent solutions misses the mark, Pervez stresses, highlighting that the majority of autistic individuals do not seek a cure; rather, they wish to be embraced within their communities. The continued focus on a singular cure overlooks the past several decades of research emphasizing the acceptance and understanding of autism as a developmental condition.

As the discourse on autism evolves, it is imperative that we prioritize scientific integrity and the voices of autistic individuals over sensational claims.